Šalis: Kanada
kalba: anglų
Šaltinis: Health Canada
SILDENAFIL (SILDENAFIL CITRATE)
PHARMASCIENCE INC
G04BE03
SILDENAFIL
100MG
TABLET
SILDENAFIL (SILDENAFIL CITRATE) 100MG
ORAL
4/30
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0136261003; AHFS:
APPROVED
2012-11-13
PRODUCT MONOGRAPH PR PMS-SILDENAFIL Sildenafil tablets (as sildenafil citrate) 25 mg, 50 mg and 100 mg cGMP-Specific Phosphodiesterase Type 5 Inhibitor Treatment of Erectile Dysfunction PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Ave., Suite 100 August 9, 2016 Montreal, Quebec H4P 2T4 www.pharmascience.com SUBMISSION CONTROL NO: 196963 _ _ _ _ _pms-SILDENAFIL Product Monograph _ _Page 2 of 49_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................. 3 SUMMARY PRODUCT INFORMATION..................................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................................... 3 CONTRAINDICATIONS ................................................................................................................ 3 WARNINGS AND PRECAUTIONS .............................................................................................. 4 ADVERSE REACTIONS ................................................................................................................ 7 DRUG INTERACTIONS .............................................................................................................. 13 DOSAGE AND ADMINISTRATION .......................................................................................... 16 OVERDOSAGE ............................................................................................................................. 17 ACTION AND CLINICAL PHARMACOLOGY ......................................................................... 18 STORAGE AND STABILITY ...................................................................................................... 21 SPECIAL HANDLING INSTRUCTIONS .................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING.......................................................... 21 PART II: SCIENTIFIC INFORMATION .............. Perskaitykite visą dokumentą